J.R. Rahn

From Pharma To Psychedelics, Robert Barrow, CEO Of MindMed: Meet Our Speakers

EXCLUSIVE: MindMed CEO Rob Barrow On Growth Aspirations, Development Pipeline

EXCLUSIVE: Kevin O'Leary Unpacks Deal Flow, Investments, Perspectives On Disruptive Innovation

EXCLUSIVE: MindMed CEO Rob Barrow On Growth Aspirations, Development Pipeline

EXCLUSIVE: Kevin O'Leary Unpacks Deal Flow, Investments, Perspectives On Disruptive Innovation

Fintech Focus Roundup For June 13, 2021

J.R. Rahn Steps Down As MindMed CEO

Fintech Focus Roundup For June 13, 2021

J.R. Rahn Steps Down As MindMed CEO

Cannabis Movers & Shakers: The Parent Company, MindMed, Australis, Flourish Software

EXCLUSIVE: MindMed CEO Talks Mission To 'Discover, Develop And Deploy' Psychedelics

J.R. Rahn Recent News

Fintech Focus Roundup For May 2, 2021

MindMed's Nasdaq Listing Enables Institutions Diversified Access To A New Age Of Medicine

Mind Medicine (MindMed) Inc (NASDAQ: MNMD) (NEO: MMED), a leading medicine biotech company in psychedelics, this week began trading on the Nasdaq exchange.

Psychedelics Stock MindMed Debuts On Nasdaq

Mind Medicine Inc. (NASDAQ: MNMD) commenced trading its subordinate voting shares on The Nasdaq Capital Market Tuesday, under the ticker symbol “MNMD,” as

Psychedelics Stock MindMed Skyrockets On The News Of Nasdaq Trading

Mind Medicine Inc. (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ) confirmed Monday it will commence trading on the Nasdaq Capital Market under the ticker symbol “MNMD” on April 27th.

Fintech Focus Roundup For February 20, 2020

Is MindMed Creating The Tesla Of Mental Health? Thoughts From CEO JR Rahn, Investor Kevin O'Leary

Mind Medicine (OTC: MMEDF) Co-Founder and CEO J.R.

Fintech Focus Roundup For November 28, 2020